128 related articles for article (PubMed ID: 24129679)
1. Skin tumorigenesis stimulated by Raf inhibitors relies upon Raf functions that are dependent and independent of ERK.
Doma E; Rupp C; Varga A; Kern F; Riegler B; Baccarini M
Cancer Res; 2013 Dec; 73(23):6926-37. PubMed ID: 24129679
[TBL] [Abstract][Full Text] [Related]
2. Antitumor efficacy of the novel RAF inhibitor GDC-0879 is predicted by BRAFV600E mutational status and sustained extracellular signal-regulated kinase/mitogen-activated protein kinase pathway suppression.
Hoeflich KP; Herter S; Tien J; Wong L; Berry L; Chan J; O'Brien C; Modrusan Z; Seshagiri S; Lackner M; Stern H; Choo E; Murray L; Friedman LS; Belvin M
Cancer Res; 2009 Apr; 69(7):3042-51. PubMed ID: 19276360
[TBL] [Abstract][Full Text] [Related]
3. Antitumor activity of the selective pan-RAF inhibitor TAK-632 in BRAF inhibitor-resistant melanoma.
Nakamura A; Arita T; Tsuchiya S; Donelan J; Chouitar J; Carideo E; Galvin K; Okaniwa M; Ishikawa T; Yoshida S
Cancer Res; 2013 Dec; 73(23):7043-55. PubMed ID: 24121489
[TBL] [Abstract][Full Text] [Related]
4. Essential, non-redundant roles of B-Raf and Raf-1 in Ras-driven skin tumorigenesis.
Kern F; Doma E; Rupp C; Niault T; Baccarini M
Oncogene; 2013 May; 32(19):2483-92. PubMed ID: 22733131
[TBL] [Abstract][Full Text] [Related]
5. [Cellular and molecular mechanisms of carcinogenic side effects and resistance to BRAF inhibitors in metastatic melanoma with BRAFV600 mutation: state of the knowledge].
Capovilla M
Ann Pathol; 2013 Dec; 33(6):375-85. PubMed ID: 24331719
[TBL] [Abstract][Full Text] [Related]
6. RAF inhibitors that evade paradoxical MAPK pathway activation.
Zhang C; Spevak W; Zhang Y; Burton EA; Ma Y; Habets G; Zhang J; Lin J; Ewing T; Matusow B; Tsang G; Marimuthu A; Cho H; Wu G; Wang W; Fong D; Nguyen H; Shi S; Womack P; Nespi M; Shellooe R; Carias H; Powell B; Light E; Sanftner L; Walters J; Tsai J; West BL; Visor G; Rezaei H; Lin PS; Nolop K; Ibrahim PN; Hirth P; Bollag G
Nature; 2015 Oct; 526(7574):583-6. PubMed ID: 26466569
[TBL] [Abstract][Full Text] [Related]
7. A new water soluble MAPK activator exerts antitumor activity in melanoma cells resistant to the BRAF inhibitor vemurafenib.
Graziani G; Artuso S; De Luca A; Muzi A; Rotili D; Scimeca M; Atzori MG; Ceci C; Mai A; Leonetti C; Levati L; Bonanno E; Tentori L; Caccuri AM
Biochem Pharmacol; 2015 May; 95(1):16-27. PubMed ID: 25795251
[TBL] [Abstract][Full Text] [Related]
8. Dimerization of the kinase ARAF promotes MAPK pathway activation and cell migration.
Mooz J; Oberoi-Khanuja TK; Harms GS; Wang W; Jaiswal BS; Seshagiri S; Tikkanen R; Rajalingam K
Sci Signal; 2014 Aug; 7(337):ra73. PubMed ID: 25097033
[TBL] [Abstract][Full Text] [Related]
9. PLX-4032, a small-molecule B-Raf inhibitor for the potential treatment of malignant melanoma.
Smalley KS
Curr Opin Investig Drugs; 2010 Jun; 11(6):699-706. PubMed ID: 20496265
[TBL] [Abstract][Full Text] [Related]
10. Cutaneous side effects of inhibitors of the RAS/RAF/MEK/ERK signalling pathway and their management.
Manousaridis I; Mavridou S; Goerdt S; Leverkus M; Utikal J
J Eur Acad Dermatol Venereol; 2013 Jan; 27(1):11-8. PubMed ID: 22540151
[TBL] [Abstract][Full Text] [Related]
11. Paradoxical activation of T cells via augmented ERK signaling mediated by a RAF inhibitor.
Callahan MK; Masters G; Pratilas CA; Ariyan C; Katz J; Kitano S; Russell V; Gordon RA; Vyas S; Yuan J; Gupta A; Wigginton JM; Rosen N; Merghoub T; Jure-Kunkel M; Wolchok JD
Cancer Immunol Res; 2014 Jan; 2(1):70-9. PubMed ID: 24416731
[TBL] [Abstract][Full Text] [Related]
12. B-Raf inhibition in conjunctival melanoma cell lines with PLX 4720.
Riechardt AI; Maier AK; Nonnenmacher A; Reichhart N; Keilholz U; Kociok N; Strauss O; Joussen AM; Gundlach E
Br J Ophthalmol; 2015 Dec; 99(12):1739-45. PubMed ID: 26347528
[TBL] [Abstract][Full Text] [Related]
13. Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer.
Roberts PJ; Der CJ
Oncogene; 2007 May; 26(22):3291-310. PubMed ID: 17496923
[TBL] [Abstract][Full Text] [Related]
14. Targeting RAS/RAF/MEK/ERK signaling in metastatic melanoma.
Wang AX; Qi XY
IUBMB Life; 2013 Sep; 65(9):748-58. PubMed ID: 23893853
[TBL] [Abstract][Full Text] [Related]
15. Different effects of point mutations within the B-Raf glycine-rich loop in colorectal tumors on mitogen-activated protein/extracellular signal-regulated kinase kinase/extracellular signal-regulated kinase and nuclear factor kappaB pathway and cellular transformation.
Ikenoue T; Hikiba Y; Kanai F; Aragaki J; Tanaka Y; Imamura J; Imamura T; Ohta M; Ijichi H; Tateishi K; Kawakami T; Matsumura M; Kawabe T; Omata M
Cancer Res; 2004 May; 64(10):3428-35. PubMed ID: 15150094
[TBL] [Abstract][Full Text] [Related]
16. Germline mutations of MEK in cardio-facio-cutaneous syndrome are sensitive to MEK and RAF inhibition: implications for therapeutic options.
Senawong T; Phuchareon J; Ohara O; McCormick F; Rauen KA; Tetsu O
Hum Mol Genet; 2008 Feb; 17(3):419-30. PubMed ID: 17981815
[TBL] [Abstract][Full Text] [Related]
17. Raf kinases in cancer-roles and therapeutic opportunities.
Maurer G; Tarkowski B; Baccarini M
Oncogene; 2011 Aug; 30(32):3477-88. PubMed ID: 21577205
[TBL] [Abstract][Full Text] [Related]
18. 1Alpha,25-dihydroxyvitamin D3-mediated stimulation of steroid sulphatase activity in myeloid leukaemic cell lines requires VDRnuc-mediated activation of the RAS/RAF/ERK-MAP kinase signalling pathway.
Hughes PJ; Brown G
J Cell Biochem; 2006 Jun; 98(3):590-617. PubMed ID: 16440327
[TBL] [Abstract][Full Text] [Related]
19. New perspectives on targeting RAF, MEK and ERK in melanoma.
Dumaz N; Lebbé C
Curr Opin Oncol; 2021 Mar; 33(2):120-126. PubMed ID: 33332926
[TBL] [Abstract][Full Text] [Related]
20. Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma.
Trunzer K; Pavlick AC; Schuchter L; Gonzalez R; McArthur GA; Hutson TE; Moschos SJ; Flaherty KT; Kim KB; Weber JS; Hersey P; Long GV; Lawrence D; Ott PA; Amaravadi RK; Lewis KD; Puzanov I; Lo RS; Koehler A; Kockx M; Spleiss O; Schell-Steven A; Gilbert HN; Cockey L; Bollag G; Lee RJ; Joe AK; Sosman JA; Ribas A
J Clin Oncol; 2013 May; 31(14):1767-74. PubMed ID: 23569304
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]